Fig. 10
Liver disease-relevant pMHCII-NPs spare general immunity. a rVV titers in ovaries 4 and 14 days after rVV infection (n = 3–4/group). b Influenza viral titers in lungs 3 and 7 days after infection with PR8 with or without HKx31 priming (n = 5, 3, 4, 5 and 5; left to right). c Clinical scores and body weight (n = 5 mice/group). d Colony-forming units of L. monocytogenes in the spleen and livers 3, 7, and 14 days after infection (n = 4, 3, 3, 5, 3 and 4; left to right). e Serum anti-DNP antibody titers upon KLH–DNP immunization (n = 3/group). f–k Percentages of tetramer+ cells (f), macroscopic PBC scores and liver weight (g), microscopic PBC scores (h), liver images (i), microscopic tumor scores (j), and survival rates (k) of untreated vs. PDC166–181/IAg7-NP-treated NOD.c3c4 (n = 5/group) or untreated Balb/c mice (n = 7) challenged with CT26 cells (overlapping 100% survival in untreated vs. PDC166–181/IAg7-NP-treated mice). Scale bar in (i): 100 μm. l–p Percentages of tetramer+ cells (l), macroscopic (m), and microscopic PBC scores (n), and liver weight and metastasis number (o), and liver images (p) of untreated vs. PDC166–181/IAg7-NP-treated NOD.c3c4 (n = 5 and 4) or untreated B6 mice (n = 6) challenged with B16/F10 cells. q Survival rates of the mice in l–p (overlapping 100% survival in untreated vs. PDC166–181/IAg7-NP-treated mice). Data correspond to mean ± SEM. P values were compared via Mann–Whitney U except for k, q (log-rank), or c (two-way ANOVA)
